MIRUM PHARMACEUTICALS INC (MIRM)
Health Care · Rare disease biopharmaceuticals · NASDAQ
Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic liver disease and viral hepatitis.
What MIRUM PHARMACEUTICALS INC does
Mirum Pharmaceuticals is a biopharmaceutical company focused on transforming the treatment of rare and orphan diseases. The company markets three approved medicines: Livmarli (maralixibat), an IBAT inhibitor for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis; Cholbam (cholic acid) for bile acid synthesis disorders and peroxisomal disorders; and Ctexli (chenodiol) for cerebrotendinous xanthomatosis. The company is also advancing late-stage development candidates including volixibat for cholestatic liver diseases and brelovitug for chronic hepatitis D infection.
Themes: ["rare cholestatic diseases","bile acid disorders","orphan drugs","hepatic diseases","monoclonal antibodies","viral hepatitis"]
Fundamentals
- Price$127.70 as of 2026-07-09 close
- Market cap$7.8B as of 2026-07-10
- 1-year return+138.9% as of 2026-07-09 close
- Net margin-140.2% as of 2026-07-10
- Gross margin+81.4% as of 2026-07-10
- ROE-289.3% as of 2026-07-10
- Debt / equity1.28 as of 2026-07-10
- Revenue growth (YoY)+50.2% as of 2026-07-10
- Revenue CAGR (3y)+89.1% SEC XBRL
- Beta0.50 as of 2026-07-10
Key risks (from latest filing)
["Heavy dependence on successful commercialization of Livmarli and Cholbam/Ctexli; market adoption risk for these specialized rare disease medicines","Clinical development risk for volixibat, brelovitug, and MRM-3379; failure to meet development timelines or regulatory approval could impair future revenue growth","Significant operating losses and negative net margin (-140%) with limited profitability path; dependence on capital markets for funding continued R&D and commercialization"]
Competitors & peers
- Intercept Pharmaceuticals (ICPT)
- Gilead Sciences (GILD)
- Regeneron (REGN)
- Alnylam Pharmaceuticals (ALNY)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.